Blueshift Asset Management LLC Buys 1,290 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Blueshift Asset Management LLC lifted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 53.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,716 shares of the medical research company’s stock after buying an additional 1,290 shares during the period. Blueshift Asset Management LLC’s holdings in IQVIA were worth $881,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Versant Capital Management Inc increased its position in IQVIA by 733.3% during the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 110 shares during the period. Opal Wealth Advisors LLC bought a new position in shares of IQVIA in the 2nd quarter worth $27,000. Capital Performance Advisors LLP bought a new stake in shares of IQVIA during the third quarter worth about $27,000. Park Place Capital Corp acquired a new position in IQVIA during the 3rd quarter valued at about $28,000. Finally, Itau Unibanco Holding S.A. bought a new stake in IQVIA during the 2nd quarter worth approximately $29,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Trading Up 0.1 %

Shares of IQV opened at $201.44 on Thursday. The firm’s 50 day simple moving average is $220.36 and its 200 day simple moving average is $226.57. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The company has a market capitalization of $36.56 billion, a P/E ratio of 26.44, a P/E/G ratio of 2.10 and a beta of 1.51. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on IQV shares. The Goldman Sachs Group cut their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Barclays lowered their target price on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a report on Friday, November 1st. BTIG Research reduced their price objective on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Royal Bank of Canada reissued an “outperform” rating and set a $270.00 target price on shares of IQVIA in a research report on Friday, November 1st. Finally, Robert W. Baird decreased their price target on IQVIA from $256.00 to $223.00 and set a “neutral” rating for the company in a research report on Friday, November 1st. Five research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $256.50.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.